World Health Organization Director-General Tedros Adhanom Ghebreyesus reported 4,449 confirmed Ebola cases in the Democratic Republic of Congo on Aug. 11, 2026 [1].
The scale of the outbreak threatens to destabilize regional health security, requiring an international coordinated response to prevent the virus from crossing borders.
During a press conference at the WHO headquarters in Geneva, Tedros said that the death toll in the Democratic Republic of Congo has reached 2,061 [1]. He said that while the situation is critical, it does not currently meet the criteria for a global crisis.
"The risk of Ebola spreading in the region remains high, but we are not facing a pandemic emergency," Tedros said [2].
The organization is focusing on containment and medical intervention within the affected zones. This strategy involves a combination of rapid testing and the deployment of specialized medical personnel to the heart of the outbreak.
Dr. Matshidiso Moeti, the WHO Regional Director for Africa, said that the organization has deployed additional vaccine teams to the affected areas and is scaling up treatment capacity [2]. These efforts aim to reduce the mortality rate and stop the chain of transmission among local populations.
Health officials are monitoring the movement of people across borders to mitigate the high regional risk. The current figures reported on Aug. 11, 2026, underscore the severity of the viral spread in the Congo [1].
WHO teams continue to work with local authorities to ensure that treatment centers are equipped to handle the influx of patients. The agency said that early detection remains the most effective tool in preventing further deaths.
“"The risk of Ebola spreading in the region remains high, but we are not facing a pandemic emergency."”
The distinction between a 'high regional risk' and a 'pandemic emergency' is a critical regulatory signal from the WHO. By avoiding the pandemic label, the WHO prevents global panic and unnecessary travel restrictions while still alerting neighboring countries to heighten surveillance. The high fatality rate—nearly 46% of confirmed cases—indicates a significant gap in early treatment access that the current vaccine scale-up intends to close.
